Last reviewed · How we verify
Bendamustine, Velcade and Dexamethasone
Bendamustine is a nitrogen mustard alkylating agent that cross-links DNA, Velcade is a proteasome inhibitor that blocks the 26S proteasome, Dexamethasone is a corticosteroid that inhibits phospholipase A2.
Bendamustine is a nitrogen mustard alkylating agent that cross-links DNA, Velcade is a proteasome inhibitor that blocks the 26S proteasome, Dexamethasone is a corticosteroid that inhibits phospholipase A2. Used for Multiple myeloma.
At a glance
| Generic name | Bendamustine, Velcade and Dexamethasone |
|---|---|
| Also known as | Robimustin : Bendamustine, Velcade : Bortezomib, Dexamethasone |
| Sponsor | Intergroupe Francophone du Myelome |
| Drug class | Alkylating agent, Proteasome inhibitor, Corticosteroid |
| Target | DNA, Proteasome, Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bendamustine works by inducing DNA damage and apoptosis in cancer cells, Velcade blocks the proteasome and inhibits protein degradation, Dexamethasone has anti-inflammatory and immunosuppressive effects.
Approved indications
- Multiple myeloma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Nausea
Key clinical trials
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE2)
- Optimising Renal Outcome in Myeloma Renal Failure (PHASE2)
- Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma (PHASE2)
- Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma (PHASE1, PHASE2)
- Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM (PHASE2)
- Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy (PHASE2)
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma (PHASE2)
- Study of Mantle Cell Lymphoma Treatment by RiBVD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: